

ASX Announcement

Racura Oncology Piggyback Options Expiry Reminder

8 May 2026

Racura Oncology Limited (“Racura”) wishes to remind optionholders that the RAOPT43 options (Piggyback Options) expire on 29 May 2026. Each Piggyback Option entitles the holder to subscribe for one (1) share, exercisable at \$1.25 per option, on or before 29 May 2026, 5:00pm (AEST).

The Options Prospectus dated 22 November 2023 contains information about the Piggyback Option Offers. You should carefully read the Prospectus before exercising your options.

Racura Oncology CEO and Managing Director, Dr Daniel Tillett said: *“We are grateful for the support of all shareholders who have converted their Piggyback Options to date. If the Piggyback Options are exercised in full, Racura will be funded to undertake the first stage of the Phase 3 clinical trial of RC220 in Acute Myeloid Leukaemia. We encourage any optionholders that wish to exercise their options to do so soon to avoid potential bank transfer problems.”*

The Racura team thanks all shareholders for their continued support.

-ENDS-

Frequently Asked Questions

What should I do if I did not receive my options paperwork from Automic?

Holding Statements are mailed to the registered address (or emailed) according to the records held by Automic. If you did not receive this or can't locate your paperwork, please contact Automic by phone on 1300 288 664 (Australia), or +61 2 9698 5414 (overseas) or by emailing hello@automicgroup.com.au. Alternatively, you can download the option form from your Automic account (see following answer).

How do I exercise my options?

You can access your personalised *Notice of Exercise of Options (Form)* via Automic by taking one of the steps listed on the next page.

I already have an online account with the Automic Share registry	• Please visit https://portal.automic.com.au/investor/home • Select: “Existing Users Sign In”. • Make sure you have added your SRN to your account. • Once you have successfully signed in, click on “Documents and Statements”. • Download the <i>RACOPT43 Option Exercise Form</i>. • Submit your payment using the payment details provided on your Form.
I don’t have an online account with Automic – but wish to register for one	• Please visit https://singleholding.automic.com.au/signup • Select: “<i>Racura Oncology Limited</i>” from the dropdown list in the ISSUER field. • Enter your holder number HIN or SRN (from your latest Holding Statement). • Enter your Postcode (Aust only) or Country of Residence (if not Australia). • Tick box “<i>I am not a robot</i>”, then Next and Complete prompts. • Once you have successfully signed in, click on “<i>Documents and Statements</i>”. • Download the <i>RACOPT43 Option Exercise Form</i>. • Submit your payment using the payment details provided on Form.
I don’t have an online account with Automic – but want to use Automic for the Offers only	• Please visit https://singleholding.automic.com.au/login • Select: “<i>Racura Oncology Limited</i>” from the dropdown list in the ISSUER field. • Enter your holder number HIN or SRN (from your latest Holding Statement). Enter your Postcode (Aust only) or Country of Residence (if not Australia). Tick box “<i>I am not a robot</i>”, then Access. • Once you have successfully signed in, click on “Documents and Statements”. • Download the <i>RACOPT43 Option Exercise Form</i>. • Submit your payment using the payment details provided on Form.

How do I find my SRN?

Your Securityholder Reference Number (SRN) is listed on the holding statement sent to your registered address, as shown below, circled in red – all SRNs start with the letter “I” followed by an 11-digit number.



Your SRN is listed on your holding statement.

Note: SRN's start with a capital letter “I” followed by an 11-digit number.

Holding Statement

UNL OPTIONS EXP 14/12/2019 @ \$0.067 ESCROWED UNTIL 01/01/23

Date	Transaction	Qty On/Off	Balance	Transaction Price	NAV	Value
01 Jan 2006	Opening balance		0	-	-	-
14 Mar 2016	Placement	100,000	100,000	-	-	-
06 Jun 2016	Off-Market Transfer	(100)	99,900	-	-	-
14 Jun 2016	Option Exercise	100,000	199,900	-	-	-
14 Jun 2016	option exercise	(10,000)	189,900	\$0.00	-	\$0.00
07 Mar 2024	Closing balance		189,900	-	-	-


If you cannot locate, or did not receive a holding statement, please contact Automic by phone on 1300 288 664 (Australia) or +61 2 9698 5414 (overseas) or by emailing hello@automicgroup.com.au to request a new statement.

The SRN for the Piggyback Options is the same as that used for the Bonus Options issued in 2023 so if you have an old holding statement or option exercise form from the Bonus Option issue then you will find the SRN on there.

How do I add my SRN to my Automic account?

Please follow the instructions on how to register or log in to your existing Automic account.

Once logged into your Automic account, select “Add holding” (shown circled in the image below). Click on the “proceed to add holding” button. This will bring up the “Add Holding” form.



Enter “Racura” as the Issuer and then enter your SRN in the SRN/HIN box, check the “I’m not a robot” box, and then press the “submit request” button.

Add Holding

LINK YOUR ACCOUNTS

To manage multiple accounts from the one login, please enter a HIN or SRN below and an Automic representative will respond within two business days.



ISSUER *

Issuer code or name

HIN/SRN *

e.g. X12345678 or I12345678

☐ I'm not a robot



cancel

submit request

Your SRN holding will become visible in your Automic account after Automic processes the request which typically takes less than a day.

How do I find out how many Piggyback Options I have?

You can see your options in your Automic account if you have added your SRN (see previous answer). Your Piggyback Options are listed under their code RACOPT43. You will only have Piggyback Options if you participated in the previous Bonus Option Issue from 2023.


SRN	[REDACTED] - DR DANIEL TILLET	
RAC	Racura Oncology Ltd	
Code	Name	
RAC	ORDINARY FULLY PAID SHARES	
RACESC3	ESCROWED SHARES - 14/11/2023	
RACOPT19	UNL OPTS @ \$0.099 EXP 31/08/2021	
RACOPT20	UNL C	11/11/2022
RACOPT26	UNLIS	.65 EXP 29/11/2028
RACOPT27	UNLIS	.50 EXP 16/05/2022
RACOPT39	UNLISTED OPTIONS @ \$0.75 EXP 4/6/2024	
RACOPT40	UNLISTED OPTIONS @ \$4.25 EXP 29/11/2028	
RACOPT41	UNLISTED OPTIONS @ \$1.45 EXP 29/11/2028	
RACOPT43	UNLISTED OPTIONS @ \$1.25 EXP 29/5/2026	
RACOPT49	UNL OPT @ \$1.67 EXP 30/06/2029	

What happens once I've exercised my Piggyback Options?

Upon exercise the Piggyback Options, holders will be issued Ordinary Shares. The Ordinary Shares will be issued to the same SRN that previously held the Piggyback Options. You will be able to see your Ordinary Shares online once issued if you log into your Automic account and have added your SRN.

How do I find the Options form on the Automic website?

Log into your Automic account once you have added your SRN. Click on the “*Documents & Statements*” menu on the left-hand side of the page. This will bring up the following page.



HOLDER NUMBER	REGISTRATION NAME	CREATED	SECURITY CODE	ISSUER	DOCUMENT NAME
I*****00	DR DANIEL TILLET	10/12/2025		Racura Oncology Ltd	RACOPT43 Options Exercise Form

If you can’t see the RACOPT43 Option Exercise Form on the first page, select “*Other documents*” from the CATERGORY menu and enter “*Options*” in the KEYWORDS box, and press the green “*Search*” button. You can then download the form with all the detail on how to pay, by clicking on the download icon.

Further Information

If you have any questions regarding your options or the exercise process, please contact Automic on 1300 288 664 (within Australia), +61 2 9698 5414 (from overseas) between 8:30am to 7:00pm (AEST) or by emailing corporate.actions@automicgroup.com.au.

For other questions, you should consult your stockbroker, solicitor, accountant or other suitably qualified professional adviser.

About Racura Oncology

Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to silence cancer.

Racura's lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent silencing of the important cancer growth regulator MYC. (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients with a well-characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provides for 20 years of patent protection over (E,E)-bisantrene.

Racura is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.

Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com.

If you have any questions on this announcement, or any past Racura Oncology announcements, please visit our [Interactive Announcements](#) page.

Racura encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by

Daniel Tillett, CEO

info@racuraoncology.com

Media Contact

Cherie Hartley +61 418 737 020

cherie.hartley@irdepartment.com.au